Meredith Cook - Feb 12, 2025 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
SR. VP, GENERAL COUNSEL & SEC.
Signature
/s/ Meredith W. Cook
Stock symbol
ANIP
Transactions as of
Feb 12, 2025
Transactions value $
-$108,307
Form type
4
Date filed
2/18/2025, 08:12 PM
Previous filing
Jan 13, 2025
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Award $0 +17K +30.54% $0.00 72.6K Feb 12, 2025 Direct F1
transaction ANIP Common Stock Award $0 +11.3K +15.59% $0.00 83.9K Feb 12, 2025 Direct F2
transaction ANIP Common Stock Sale -$23.8K -400 -0.48% $59.54 83.5K Feb 13, 2025 Direct F3
transaction ANIP Common Stock Tax liability -$84.5K -1.43K -1.72% $58.92 82K Feb 14, 2025 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025.
F2 These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
F3 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2024.
F4 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,690 shares of restricted stock, the grant of which was previously reported.